OPTO-BLUE: An Integrated Bidirectional Optogenetic Lentiviral Platform for Controlled Light-Induced Gene Expression.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
31 May 2023
Historique:
received: 01 05 2023
revised: 27 05 2023
accepted: 30 05 2023
medline: 12 6 2023
pubmed: 10 6 2023
entrez: 10 6 2023
Statut: epublish

Résumé

Regulated systems for transgene expression are useful tools in basic research and a promising platform in biomedicine due to their regulated transgene expression by an inducer. The emergence of optogenetics expression systems enabled the construction of light-switchable systems, enhancing the spatial and temporal resolution of a transgene. The LightOn system is an optogenetic tool that regulates the expression of a gene of interest using blue light as an inducer. This system is based on a photosensitive protein (GAVPO), which dimerizes and binds to the UASG sequence in response to blue light, triggering the expression of a downstream transgene. Previously, we adapted the LightOn system to a dual lentiviral vector system for neurons. Here, we continue the optimization and assemble all components of the LightOn system into a single lentiviral plasmid, the OPTO-BLUE system. For functional validation, we used enhanced green fluorescent protein (EGFP) as an expression reporter (OPTO-BLUE-EGFP) and evaluated the efficiency of EGFP expression by transfection and transduction in HEK293-T cells exposed to continuous blue-light illumination. Altogether, these results prove that the optimized OPTO-BLUE system allows the light-controlled expression of a reporter protein according to a specific time and light intensity. Likewise, this system should provide an important molecular tool to modulate gene expression of any protein by blue light.

Identifiants

pubmed: 37298488
pii: ijms24119537
doi: 10.3390/ijms24119537
pmc: PMC10253389
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Agencia Nacional de Investigación y Desarrollo
ID : VIU20P0060
Organisme : Universidad de Antofagasta
ID : SEM 18-4

Références

Mol Ther Methods Clin Dev. 2021 Apr 16;21:574-584
pubmed: 34095341
ACS Synth Biol. 2023 Mar 17;12(3):664-671
pubmed: 36891673
Curr Opin Biotechnol. 1997 Oct;8(5):608-16
pubmed: 9353233
Nucleic Acids Res. 2020 Apr 6;48(6):e33
pubmed: 31989175
Science. 2002 Feb 1;295(5556):868-72
pubmed: 11786607
Biochemistry. 2008 Jul 8;47(27):7012-9
pubmed: 18553928
Curr Protoc Chem Biol. 2013;5(2):111-29
pubmed: 23839993
BMC Biotechnol. 2021 Feb 4;21(1):13
pubmed: 33541329
Nat Methods. 2012 Feb 12;9(3):266-9
pubmed: 22327833
Acta Pharm Sin B. 2020 Sep;10(9):1741-1753
pubmed: 33088693
Science. 2013 Dec 6;342(6163):1203-8
pubmed: 24179156
Gene Ther. 2017 May;24(5):298-307
pubmed: 28346436
Curr Opin Biotechnol. 2009 Aug;20(4):449-60
pubmed: 19762224
PLoS One. 2018 Jul 20;13(7):e0201028
pubmed: 30028876
Nucleic Acids Res. 2013 Apr;41(7):e77
pubmed: 23355611
Biochem Biophys Res Commun. 2015 Oct 2;465(4):769-76
pubmed: 26301633
Appl Microbiol Biotechnol. 2018 May;102(9):3849-3863
pubmed: 29569180
Biochem Biophys Res Commun. 2013 Oct 25;440(3):419-23
pubmed: 24095689
Appl Microbiol Biotechnol. 2017 Apr;101(7):2629-2640
pubmed: 28210796
Biochem J. 2012 May 1;443(3):603-18
pubmed: 22507128
Methods Mol Biol. 2016;1382:107-14
pubmed: 26611582
Dev Growth Differ. 2021 Apr;63(3):189-198
pubmed: 33733477
Nat Methods. 2011 Jan;8(1):35-8
pubmed: 21191370
J Biol Chem. 2010 Apr 9;285(15):11033-8
pubmed: 20147748
Development. 2020 Jun 17;147(12):
pubmed: 32414936
Adv Exp Med Biol. 2021;1293:235-246
pubmed: 33398817
Mol Ther. 2005 Aug;12(2):189-211
pubmed: 15946903
Biochim Biophys Acta Mol Cell Res. 2018 Nov;1865(11 Pt A):1579-1589
pubmed: 30327199
Nat Commun. 2021 Jan 27;12(1):615
pubmed: 33504786
Cells. 2019 Jul 30;8(8):
pubmed: 31366153

Auteurs

Duxan Arancibia (D)

Departamento Biomédico, Facultad de Ciencias de la Salud, Universidad de Antofagasta, Antofagasta 1240000, Chile.

Iracy Pol (I)

Departamento Biomédico, Facultad de Ciencias de la Salud, Universidad de Antofagasta, Antofagasta 1240000, Chile.

Martín Vargas-Fernández (M)

Departamento Biomédico, Facultad de Ciencias de la Salud, Universidad de Antofagasta, Antofagasta 1240000, Chile.

Rafaella V Zárate (RV)

Departamento Biomédico, Facultad de Ciencias de la Salud, Universidad de Antofagasta, Antofagasta 1240000, Chile.
Instituto Antofagasta, Universidad de Antofagasta, Antofagasta 1240000, Chile.

Janetti R Signorelli (JR)

Departamento Biomédico, Facultad de Ciencias de la Salud, Universidad de Antofagasta, Antofagasta 1240000, Chile.

Pedro Zamorano (P)

Departamento Biomédico, Facultad de Ciencias de la Salud, Universidad de Antofagasta, Antofagasta 1240000, Chile.
Instituto Antofagasta, Universidad de Antofagasta, Antofagasta 1240000, Chile.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH